CoChat
Sign Up
Cited by 472

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity

Jaleel, Mahaboobi, Nichols, R. Jeremy, Deak, Maria, Campbell, David G., Gillardon, Frank, Knebel, Axel, Alessi, Dario R.·2007·Biochemical Journal
DOI 10.1042/bj20070209
Open this paper in CoChat — free account

Abstract

Mutations in the LRRK2 (leucine-rich repeat kinase-2) gene cause late-onset PD (Parkinson's disease). LRRK2 contains leucine-rich repeats, a GTPase domain, a COR [C-terminal of Roc (Ras of complex)] domain, a kinase and a WD40 (Trp-Asp 40) motif. Little is known about how LRRK2 is regulated, what its physiological substrates are or how mutations affect LRRK2 function. Thus far LRRK2 activity has only been assessed by autophosphorylation and phosphorylation of MBP (myelin basic protein), which is catalysed rather slowly. We undertook a KESTREL (kinase substrate tracking and elucidation) screen in rat brain extracts to identify proteins that were phosphorylated by an activated PD mutant of LRRK2 (G2019S). This led to the discovery that moesin, a protein which anchors the actin cytoskeleton to the plasma membrane, is efficiently phosphorylated by LRRK2, at Thr558, a previously identified in-vivo-phosphorylation site that regulates the ability of moesin to bind actin. LRRK2 also phosphorylated ezrin and radixin, which are related to moesin, at the residue equivalent to Thr558, as well as a peptide (LRRKtide: RLGRDKYKTLRQIRQ) encompassing Thr558. We exploited these findings to determine how nine previously reported PD mutations of LRRK2 affected kinase activity. Only one of the mutations analysed, namely G2019S, stimulated kinase activity. Four mutations inhibited LRRK2 kinase activity (R1941H, I2012T, I2020T and G2385R), whereas the remainder (R1441C, R1441G, Y1699C and T2356I) did not influence activity. Therefore the manner in which LRRK2 mutations induce PD is more complex than previously imagined and is not only caused by an increase in LRRK2 kinase activity. Finally, we show that the minimum catalytically active fragment of LRRK2 requires an intact GTPase, COR and kinase domain, as well as a WD40 motif and a C-terminal tail. The results of the present study suggest that moesin, ezrin and radixin may be LRRK2 substrates, findings that have been exploited to develop the first robust quantitative assay to measure LRRK2 kinase activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/bj20070209

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. Paisan-Ruiz, 2004, Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease, Neuron, 44, 595, 10.1016/j.neuron.2004.10.023 · DOI
  2. Zimprich, 2004, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron, 44, 601, 10.1016/j.neuron.2004.11.005 · DOI
  3. Mata, 2006, LRRK2 in Parkinson's disease: protein domains and functional insights, Trends Neurosci., 29, 286, 10.1016/j.tins.2006.03.006 · DOI
  4. Taylor, 2006, LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?, Trends Mol. Med., 12, 76, 10.1016/j.molmed.2005.12.004 · DOI
  5. Farrer, 2005, LRRK2 mutations in Parkinson disease, Neurology, 65, 738, 10.1212/01.WNL.0000169023.51764.b0 · DOI
  6. Zabetian, 2005, A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations, Neurology, 65, 741, 10.1212/01.WNL.0000172630.22804.73 · DOI
  7. Marin, 2006, The Parkinson disease gene LRRK2: evolutionary and structural insights, Mol. Biol. Evol., 23, 2423, 10.1093/molbev/msl114 · DOI
  8. Goldberg, 2002, Identification of four candidate cGMP targets in Dictyostelium, Proc. Natl. Acad. Sci. U.S.A., 99, 6749, 10.1073/pnas.102167299 · DOI
  9. Bosgraaf, 2002, A novel cGMP signalling pathway mediating myosin phosphorylation and chemotaxis in Dictyostelium, EMBO J., 21, 4560, 10.1093/emboj/cdf438 · DOI
  10. Bosgraaf, 2003, Roc, a Ras/GTPase domain in complex proteins, Biochim. Biophys. Acta, 1643, 5, 10.1016/j.bbamcr.2003.08.008 · DOI
  11. Manning, 2002, The protein kinase complement of the human genome, Science, 298, 1912, 10.1126/science.1075762 · DOI · Paper page
  12. West, 2005, Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity, Proc. Natl. Acad. Sci. U.S.A., 102, 16842, 10.1073/pnas.0507360102 · DOI · Paper page
  13. Greggio, 2006, Kinase activity is required for the toxic effects of mutant LRRK2/dardarin, Neurobiol. Dis., 23, 329, 10.1016/j.nbd.2006.04.001 · DOI · Paper page
  14. Cohen, 2006, KESTREL: a powerful method for identifying the physiological substrates of protein kinases, Biochem. J., 393, 1, 10.1042/BJ20051545 · DOI
  15. Durocher, 2002, High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells, Nucleic Acids Res., 30, E9, 10.1093/nar/30.2.e9 · DOI
  16. Campbell, 2002, Identification of protein phosphorylation sites by a combination of mass spectrometry and solid phase Edman sequencing, J. Biomol. Techn., 13, 121
  17. Troiani, 2005, Searching for biomarkers of Aurora-A kinase activity: identification of in vitro substrates through a modified KESTREL approach, J. Proteome Res., 4, 1296, 10.1021/pr050018e · DOI
  18. Polesello, 2004, Small is beautiful: what flies tell us about ERM protein function in development, Trends Cell Biol., 14, 294, 10.1016/j.tcb.2004.04.003 · DOI
  19. Gary, 1995, Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site, Mol. Biol. Cell, 6, 1061, 10.1091/mbc.6.8.1061 · DOI
  20. Pestonjamasp, 1995, Moesin, ezrin, and p205 are actin-binding proteins associated with neutrophil plasma membranes, Mol. Biol. Cell, 6, 247, 10.1091/mbc.6.3.247 · DOI
  21. Turunen, 1994, Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family, J. Cell Biol., 126, 1445, 10.1083/jcb.126.6.1445 · DOI
  22. Pearson, 2000, Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain, Cell, 101, 259, 10.1016/S0092-8674(00)80836-3 · DOI
  23. Huang, 1999, Replacement of threonine 558, a critical site of phosphorylation of moesin in vivo, with aspartate activates F-actin binding of moesin. Regulation by conformational change, J. Biol. Chem., 274, 12803, 10.1074/jbc.274.18.12803 · DOI
  24. Nakamura, 1999, Regulation of F-actin binding to platelet moesin in vitro by both phosphorylation of threonine 558 and polyphosphatidylinositides, Mol. Biol. Cell, 10, 2669, 10.1091/mbc.10.8.2669 · DOI
  25. Matsui, 1998, Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association, J. Cell Biol., 140, 647, 10.1083/jcb.140.3.647 · DOI
  26. Oshiro, 1998, Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures, J. Biol. Chem., 273, 34663, 10.1074/jbc.273.52.34663 · DOI
  27. Tran Quang, 2000, Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes, EMBO J., 19, 4565, 10.1093/emboj/19.17.4565 · DOI
  28. Paglini, 1998, Suppression of radixin and moesin alters growth cone morphology, motility, and process formation in primary cultured neurons, J. Cell Biol., 143, 443, 10.1083/jcb.143.2.443 · DOI
  29. MacLeod, 2006, The familial Parkinsonism gene LRRK2 regulates neurite process morphology, Neuron, 52, 587, 10.1016/j.neuron.2006.10.008 · DOI
  30. McClatchey, 2005, Membrane organization and tumorigenesis – the NF2 tumor suppressor, Merlin, Genes Dev., 19, 2265, 10.1101/gad.1335605 · DOI
  31. Boudeau, 2006, Emerging roles of pseudokinases, Trends Cell Biol., 16, 443, 10.1016/j.tcb.2006.07.003 · DOI
  32. West, 2007, Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity, Hum. Mol. Genet., 16, 223, 10.1093/hmg/ddl471 · DOI · Paper page
  33. Gloeckner, 2006, The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity, Hum. Mol. Genet., 15, 223, 10.1093/hmg/ddi439 · DOI
  34. Farrer, 2007, Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia, Parkinsonism Relat. Disord., 13, 89, 10.1016/j.parkreldis.2006.12.001 · DOI

Cited by

Sorted by citations

Metadata

Authors
Jaleel, M., Nichols, R. J., Deak, M., Campbell, D. G., Gillardon, F., Knebel, A., & Alessi, D. R.
Affiliations
  • MRC Protein Phosphorylation Unit, MSI/WTB Complex, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, U.K.
  • CNS Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, D-88397 Biberach an der Riss, Federal Republic of Germany
  • Kinasource Limited, Unit 9, South Dudhope Mill, 77 Douglas Street, Dundee DD1 5AN, Scotland, U.K.
Venue
Biochemical Journal
Publisher
Portland Press Ltd.
Published
2007-06-27
Volume
405
Issue
2
Pages
307-317
ISSN
  • 0264-6021
  • 1470-8728
DOI
10.1042/bj20070209
Cited by
472
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review